Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.

about

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Current Approaches and Emerging Directions in HER2-resistant Breast Cancer.AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines.

P2860

Q28071388-BD5ACFB4-2B46-44BB-8834-0FAD69A43A33 Q34016480-18C45EDE-A9D2-47CA-8652-53D8B0825ED0 Q37225342-7E4EF5F9-4259-4595-B72C-C8627903E185

P2860

Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q39520887

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Everolimus and its role in hor ...... tant metastatic breast cancer.

@en

Everolimus and its role in hor ...... tant metastatic breast cancer.

@nl

type

Item

label

Everolimus and its role in hor ...... tant metastatic breast cancer.

@en

Everolimus and its role in hor ...... tant metastatic breast cancer.

@nl

prefLabel

Everolimus and its role in hor ...... tant metastatic breast cancer.

@en

Everolimus and its role in hor ...... tant metastatic breast cancer.

@nl

P1476

Everolimus and its role in hor ...... tant metastatic breast cancer.

@en

P2093

Alexa C Glencer

http://www.w3.org/2001/XMLSchema#string

Hope S Rugo

http://www.w3.org/2001/XMLSchema#string

Sara Keck

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

P304

1383-1396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.12.143

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23148612

http://www.w3.org/2001/XMLSchema#string

Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.

about

P2860

P2860

Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698